El interés en corto de SPX Technologies da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de SPX Technologies. Los datos de interés en corto se actualizan cada dos semanas.

SPX Technologies (NYSE:SPXC) Bolsa, Informe de interés en corto

SPX Techs

SPX Technologies

SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The detection and measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others.

SPX Technologies Inc

SINGAPORE EXCHANGE LTD by Singapore Exchange Ltd.

Singapore Exchange Ltd

SINGAPORE EXCH UNSP/ADR by Singapore Exchange Ltd.

DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSS#NYSE">DSS</a>) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc. ("Impact"), has entered into a definitive merger agreement (the "Merger Agreement") with Dr. Ashleys Limited ("Dr. Ashleys"), a global pharmaceutical company.
Under the terms of the agreement, Dr. Ashleys will acquire Impact through a reverse merger that will result in a newly formed combined entity (the "PubCo") traded on the NYSE American under the name "Dr Ashleys Limited."
This strategic transaction marks an important milestone not only for Impact, but also for DSS, as it reflects a successful outcome in the overall Company strategy to unlock value across the portfolio and for its shareholders by advancing key subsidiaries toward independent public listings and/or other exit opportunities.

News

DSS' Impact BioMedical Enters Into Definitive Merger Agreement With Dr. Ashleys

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models
Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use
FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1b Dose Finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC. CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers.

Biotech

General

CLRB

Cellectar Biosciences Submits FDA Protocol For Phase 1b Study Of CLR 125 In Relapsed Triple Negative Breast Cancer

Guggenheim analyst Michael Morris reiterates Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and maintains $165 price target.

Price Target

Reiteration

Analyst Ratings

RDDT

Guggenheim Reiterates Buy on Reddit, Maintains $165 Price Target

Primech AI Pte. Ltd. ("Primech AI" or the "Company"), a subsidiary of Primech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>), today announced the signing of a strategic partnership with Hong Kong-based ReMining Ai Ltd to expand the deployment of its revolutionary HYTRON autonomous <a href="https://www.globenewswire.com/Tracker?data=iZ7fObqGU6ZnGNY5lLVfIy5XGRRitwii5kKoE1rMQzpE2lSCgnlvg_7isAYr1wcV4XtpG54CFPtbVVVp0CnWMA97q_jZfi0z6E4P3DZMylHdZAUmCQbYfHh1Y5ml1MI6ScUsyTbB6aqyb1b6hHM_wA==">bathroom cleaning robot</a> to the Hong Kong market.
The companies formally established their collaboration through a signed Memorandum of Understanding (MOU), creating a framework for ReMining Ai Ltd to serve as Primech AI's authorized agent in Hong Kong for two years.

Global

PMEC

Primech AI Partners With ReMining Ai To Launch HYTRON Autonomous Bathroom Cleaning Robot In Hong Kong

ONDS

Ondas Holdings' American Robotics Partners With Mistral, Focusing On Joint Marketing, Sales, And Integration Of Optimus Drone System And Iron Drone Raider Into US Defense And Homeland Security Markets

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Netherton Syndrome.
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency (EMA), which granted Orphan Drug Designation to QRX003 in May 2025.

QNRX

Quoin Pharmaceuticals Receives FDA Rare Pediatric Disease Designation For QRX003 To Treat Netherton Syndrome

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $50 to $68.

CDTX

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $68

Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000&#xAE; Index and the broad-market Russell 3000&#xAE; Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution.

DERM

Journey Medical To Join Russell 2000 And Russell 3000 Indexes, Effective After The Close Of U.S. Equity Markets On June 27, 2025

Contracts

AMPG

AmpliTech Group's 5G Division Receives Follow On Order Over $1M As Part Of LOI For 5G ORAN Radios

Four-year award leverages BlackSky's real-time, AI-driven monitoring services for automated object and pattern-of-life change detection at military and economic facilities worldwide
BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) won a more than $24 million, four-year, National Geospatial-Intelligence Agency (NGA) Luno A Facility Operational Monitoring (FOMO) delivery order for global monitoring of military and economic facilities. As part of the order, BlackSky has received an initial base and surge option award of $2 million.

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Technology Bags Over $24M, 4-Yr, National Geospatial-Intelligence Agency Luno A FOMO Delivery Order For Global Monitoring Of Military And Economic Facilities

Observed 32% Q2 2025 Store-Level Sales Growth, Cold Brew Vertical, and Turkey Launch Reinforce Multi-Channel Expansion Strategy &nbsp;
BREA, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>), a leader in the specialty coffee market, today announced series of corporate developments that highlight the company's rapid growth and strategic execution in global markets.
"Reborn's recent progress reflects our ability to execute across multiple growth verticals simultaneously—from international market entry to product innovation and franchise infrastructure," said Jay Kim, CEO of Reborn Coffee. "We're building not just a coffee brand, but a global lifestyle ecosystem."
Positive Store-Level Sales Trend Observed in Q2 2025: Reborn Coffee has observed encouraging trends in its store-level sales performance during the second quarter of 2025. Compared to the same period last year, company-operated stores have experienced an average sales increase of approximately 32% to date. This growth reflects strong customer demand, effective product mix, and improved operational efficiency. While full quarterly results will be disclosed in the Company's upcoming financial reporting, Reborn remains optimistic about continued momentum across its retail and B2B channels.

Guidance

REBN

Reborn Coffee Reports 32% Q2 Store Sales Surge, Driven By Cold Brew And Turkey Expansion

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced a strategic validator partnership with the dogwifhat (WIF) community, one of the most iconic and culturally significant memecoin ecosystems on Solana.
Under this partnership, DeFi Dev Corp. will operate a dedicated dogwifhat validator node on the Solana blockchain. The validator will be owned by the dogwifhat community, with DeFi Dev Corp. providing technical operations, infrastructure, and ongoing performance management. The parties will jointly promote the validator and collaborate to secure delegated stake, including through an application to the Solana Foundation Delegation Program (SFDP).

DFDV

DeFi Development Announces Strategic Validator Partnership With dogwifhat Community

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo--
--The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the study--
--Enobosarm monotherapy had a positive safety profile with essentially no gastrointestinal side effects during the maintenance treatment period--
-- Based on efficacy and safety from Phase 2b QUALITY and Maintenance Extension study:
--Enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program--
--Veru has been granted a meeting with FDA to discuss the Phase 3 clinical program--

VERU

Veru Reports Topline Efficacy And Safety Results From Maintenance Extension Portion Of Phase 2b QUALITY Study, Demonstrating that In 12 Weeks After Stopping Semaglutide, Placebo Monotherapy Group Regained 43% Of Body Weight While Enobosarm Monotherapy Reduced Weight Regain By 46%

<a href="https://www.globenewswire.com/Tracker?data=7_VcY5I0BGcwkf_m2m9r_p87pMuC7esvQpX-MNoBJ0FV6iyH2DeAioiLdaOAW55t1E8JITLdFaoejSqRfywu6JxYUMZT6ZI6pGUFGZ4D5V4=">Ernexa Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the "SPA") entered into on March 31, 2025 with certain accredited investors.
The company issued 3,181,145 shares of common stock and 622,134 prefunded warrants and received approximately $6.0 million in gross proceeds from the issuance of such securities. The initial closing under the SPA was on April 2, 2025, where the company issued 662,269 shares of common stock and 33,983 prefunded warrants for approximately $1.1 million in gross proceeds. A remaining subscription amount under the SPA of $190,248 for 121,255 shares of common stock has not yet been received.

ERNA

Ernexa Therapeutics Receives ~$6M In Second Closing Under Securities Purchase Agreement With Certain Accredited Investors

JP Morgan analyst Tomohiko Sano initiates coverage on Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Overweight rating and announces Price Target of $500.

Initiation

JP Morgan Initiates Coverage On Carlisle Companies with Overweight Rating, Announces Price Target of $500

European artificial intelligence <a href="https://www.benzinga.com/25/05/45332493/mit-dropout-ethan-thornton-secures-100m-for-mach-industries-backed-by-sequoia-and-khosla-to-revolutionize-u-s-defense-tech">defense</a> startup Helsing<a href="https://helsing.ai/newsroom/helsing-raises-eur600m-to-invest-in-european-technological-sovereignty"> announced</a> a €600 million ($694 million) funding round on Tuesday, led by Prima Materia, the investment firm founded by Spotify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) CEO <a href="https://www.benzinga.com/general/health-care/25/01/43182414/spotify-co-founder-daniel-eks-neko-health-secures-260-million-for-us-expansion-as-it-compares-itself-with-the-apples-or-teslas-of-the-world">Daniel Ek</a> and Shakil Khan, an earlier investor in Spotify.
The company said the new funding will help advance Europe's "technological sovereignty" by scaling domestic production of AI-driven defense systems. Helsing uses artificial intelligence to support military decision-making by connecting real-time sensor and weapons system data with advanced software architectures, according to its<a href="https://helsing.ai/"> website</a>.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Founded in 2021, the company operates in Germany, France, and the U.K. Its product portfolio includes platforms like the HX-2, which reflects the company's move to integrate AI with battlefield-ready hardware. According to Helsing, its technologies are already being deployed under several government contracts, though specific client names have not been disclosed.
<h2 class="wp-block-heading">High-Profile Backers Fuel Helsing's Growth Strategy</h2>
The latest investment round includes contributions from existing stakeholders Lightspeed Venture, Accel, General Catalyst, Plural, and Swedish defense firm SAAB. New participants include BDT &amp; MSD Partners, according to Helsing.
Ek, who also serves as Helsing's chairman, said the investment reflects an urgent need to bolster Europe's security architecture amid rising global tensions. "As Europe rapidly strengthens its defense capabilities in response to evolving geopolitical challenges, there is an urgent need for investments in advanced technologies that ensure its strategic autonomy and security readiness," Ek said in the statement.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
Helsing's prior valuation stood at approximately €5 billion following a €450 million round led by General Catalyst in 2023. The company declined to confirm its current valuation due to pending regulatory approvals, <a href="https://www.cnbc.com/2025/06/17/spotifys-daniel-ek-leads-investment-in-defense-startup-helsing.html">CNBC</a> says.
<h2 class="wp-block-heading">Defense Tech Surpasses Traditional Venture Markets</h2>
The funding surge reflects a broader shift in the European investment landscape. According to the<a href="https://www.nif.fund/news/inaugural-dealroom-and-nato-innovation-fund-report-reveals-record-breaking-investing-in-startups-in-european-defence-security-and-resilience-sector/"> NATO Innovation Fund</a>, venture capital backing for defense, security, and resilience startups in Europe reached a record $5.2 billion in 2024. That figure represents a 30% increase over the past two years, despite a 45% contraction in general VC markets over the same period.
According to CNBC, ongoing conflicts such as the war in Ukraine and conflict between Israel and Iran have driven investor interest in technologies that enhance operational readiness and strategic autonomy. Helsing is among a growing list of AI-focused defense startups offering governments and militaries tools to manage complex warzones through automation and real-time intelligence.
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">Europe's AI Defense Race Accelerates</h2>
Helsing says it will use the newly raised capital to advance its AI-based software platforms and scale integrated systems like the HX-2, a mass-producible strike drone designed to operate in electronic warfare environments. The HX-2 is part of the Altra platform, which enables coordinated swarm strikes and integration with battlefield intelligence systems.
According to<a href="https://helsing.ai/company"> Helsing</a>, the company is already executing large contracts for democratic governments, though specific partners have not been disclosed.
As Europe ramps up its domestic defense capabilities, Helsing may emerge as a strategic player at the intersection of AI and national security. With financial backing from Spotify's leadership and top-tier investors, the company may play a defining role in shaping the continent's military future.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

SPOT

Spotify's $694M Bet On AI War Tech: What Daniel Ek's Helsing Move Signals For Investors Watching The Defense Boom

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS analyst Marcus Cole initiated coverage on Amrize Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRZ#NYSE">AMRZ</a>) with a Neutral rating and announced a price target of $53. Amrize shares closed at $51.99 on Monday. <a href="https://www.benzinga.com/quote/amrz/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Chris Brendler initiated coverage on Galaxy Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) with a Buy rating and announced a price target of $25. Galaxy Digital shares closed at $18.47 on Monday. <a href="https://www.benzinga.com/quote/glxy/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy rating and announced a price target of $17. Amylyx Pharmaceuticals shares closed at $5.02 on Monday. <a href="https://www.benzinga.com/quote/amlx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Maury Raycroft initiated coverage on Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) with a Hold rating and announced a price target of $3.5. Cardiff Oncology shares closed at $3.16 on Monday. <a href="https://www.benzinga.com/quote/crdf/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/AMLX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24082800/image-358-1024x585.png" alt="" class="wp-image-959787" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24082800/image-358-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24082800/image-358-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24082800/image-358-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24082800/image-358.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMRZ

CRDF

GLXY

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) will release earnings results for the fourth quarter, after the closing <a href="https://www.benzinga.com/quote/FDX/earnings">bell on Tuesday, June 23.</a>
Analysts expect the Memphis, Tennessee-based company to report quarterly earnings at $5.85 per share, up from $5.41 per share in the year-ago period. 
According to data from Benzinga Pro, FedEx projects to report quarterly revenue of $21.81 billion, compared to $22.1 billion a year earlier.
On June 9, FedEx board increased its quarterly dividend from $1.38 to $1.45 per share.
With the recent buzz around FedEx, some investors may be eyeing potential gains from the company's dividends. Currently, FedEx offers an annual dividend yield of 2.53%, which is a quarterly dividend amount of $1.45 per share ($5.80 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $237,024 or around 1,034 shares. For a more modest $100 per month or $1,200 per year, you would need $47,451 or around 207 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($5.80 in this case). So, $6,000 / $5.80 = 1,034 ($500 per month), and $1,200 / $5.80 = 207 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
FDX Price Action: Shares of FedEx rose 2.1% to close at $229.23 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Dividends

How To Earn $500 A Month From FedEx Stock Ahead Of Q4 Earnings

Jefferies analyst Maury Raycroft initiates coverage on Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) with a Hold rating and announces Price Target of $3.5.

Jefferies Initiates Coverage On Cardiff Oncology with Hold Rating, Announces Price Target of $3.5

WIIM

ONMD

OneMedNet shares are trading higher after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.

Comments

SPX Technologies

Interés en corto

SPX Technologies (NYSE:SPXC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL